Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptimUM-10 neoadjuvant darovasertib for primary non-metastatic uveal melanoma
2025-522387-32-00Phase 3Authorised
- Sponsor
- IDEAYA Biosciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of darovasertib in intraocular melanoma (4 cohorts), sponsored by IDEAYA Biosciences. Primary endpoints: Moderate to high risk of visual impairment with BCVA loss of at least 15 letters and Eye preservation rate. Planned start Apr 2026; status: authorised.
02
Drugs
darovasertib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2025-522387-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522387-32-00.